AI-driven fertility technologies expanded through clinical partnerships, research validation, workflow automation, and patient-access initiatives across the reproductive health landscape.
Fertility organizations focused on integrating AI directly into fertility workflows, including embryo assessment, ultrasound monitoring, ovarian stimulation management, patient triage, diagnostic support, and treatment planning. Companies also emphasized interoperability with existing healthcare infrastructure, particularly electronic medical records and laboratory management systems.
At the same time, fertility technology providers continued to generate research evidence supporting AI-assisted reproductive medicine. New clinical studies, peer-reviewed publications, regulatory milestones, and international partnerships demonstrated growing interest in applying machine learning and data science to improve outcomes and streamline care delivery.
Beyond clinical applications, several organizations expanded patient-facing offerings designed to improve education, affordability, and access. Digital platforms leveraged AI to provide personalized information, fertility guidance, and consumer support services, while fertility providers increasingly explored remote monitoring and virtual-care models.
The developments highlighted below illustrate how fertility-focused AI organizations are contributing to a more connected, data-driven, and patient-centered fertility ecosystem.
Cercle Names New CEO, COO, CTO
Cercle continued to expand its position as an AI infrastructure provider for fertility clinics through a combination of leadership growth, strategic partnerships, and broader deployment of its Cercle™ Biomedical Graph platform.
During 2025 and early 2026, the company strengthened its executive team with Andreas Melder being promoted to CEO,, followed by the appointment of Lucy Huang as Chief Operating Officer and Pran Punniamoorthy as Chief Technology Officer in March 2026, as reported through the company’s official blog and LinkedIn updates.
The company expanded its reach through several notable partnerships. Mid 2025, Cercle announced a partnership with Ivy Fertility, a U.S. network of fertility clinics operating across multiple EMR systems. The collaboration unified data across Ivy Fertility’s network and provided physicians with AI-supported fertility analytics and IVF outcome forecasting tools.
Cercle also entered a global distribution partnership with MedITEX in June 2025, extending access to its AI platform across fertility and genetics clinics throughout Europe.
Additional expansion occurred through Cercle’s partnership with Esco Medical, which integrated AI-assisted embryo assessment, laboratory workflow automation, and traceability tools into embryology environments.
Cycle Clarity Partners With Artisan
A significant milestone occurred in June 2025 when Cycle Clarity announced a strategic partnership with Artisan, enabling AI-generated follicular monitoring data to flow directly into the fertility EMR environment. The integration was designed to reduce manual data entry and streamline physician access to ovarian monitoring insights, according to the partnership announcement.
The company also expanded access to fertility monitoring through its ongoing collaboration with Arizona Reproductive Medicine Specialists (ARMS). As described by Arizona Fertility, the partnership supports remote ovarian ultrasound monitoring, allowing patients to obtain scans locally while Cycle Clarity’s AI platform automatically evaluates follicular growth and transmits results to fertility specialists.
In October 2025, Cycle Clarity showcased a next-generation platform update during the American Society for Reproductive Medicine (ASRM) Scientific Congress in San Antonio. The enhanced platform introduced new image annotation capabilities and workflow tools designed to improve consistency across sonographers and fertility centers, according to the company’s ASRM announcement.
Research and clinical validation remained central to Cycle Clarity’s strategy throughout 2026. Company publications highlighted evidence supporting AI-assisted follicle measurements that closely matched expert sonographer assessments. Additional workflow studies reported operational improvements and increased patient throughput following implementation of AI-guided ultrasound standardization,
Future Fertility Raises >$4 Million
Future Fertility entered 2026 with several significant milestones spanning financing, research, regulatory progress, and international commercial expansion.
In April 2026, Future Fertility announced a $4.1 million financing round led by M Ventures, with participation from Whitecap Venture Partners, Sandpiper Ventures, Gaingels, and Jolt VC, according to coverage from Femtech Insider. The company said the funding would support commercialization efforts, regulatory initiatives, and continued development of its AI-enabled fertility technologies.
In early 2026, Future Fertility announced an FDA 513(g) determination related to ROSE™, its AI-based oocyte assessment platform. The development was referenced in coverage of the company's April 2026 financing announcement by FemTech World.
Research activity remained particularly prominent. According to the company’s research portal, Future Fertility contributed publications in journals including Human Reproduction, Fertility & Sterility, Reproductive BioMedicine Online, and Nature Scientific Reports. Studies examined AI-assisted prediction of blastocyst development, donor-oocyte quality assessment, endometrial receptivity analysis, and non-invasive prediction of reproductive outcomes.
During 2025 and 2026, Future Fertility reported continued commercial and research activity related to its AI-enabled fertility technologies, including a partnership with Japan’s Kato Ladies Clinic.
In addition to oocyte assessment, Future Fertility introduced an AI model for evaluating endometrial receptivity from ultrasound images, presenting new research findings during the 2025 ASRM Scientific Congress. Combined with its growing research portfolio and expanding global partnerships, these developments reinforced Future Fertility’s position as a research-driven fertility AI company operating across multiple international markets.
LEVY Health
In October 2025, Levy Health announced a collaboration with IVF Academy USA, providing fertility trainees with access to AI-supported clinical decision tools and guideline-based educational resources.
Rescripted Grows AI Tool, Clara
Rescripted expanded its role in fertility and women’s health technology through the launch of a dedicated large language model, new consumer services, strategic partnerships, and continued audience growth.
In September 2025, the company introduced Clara, a large language model built specifically for women’s health. According to the launch announcement covered by Fitt Insider and highlighted by company leadership on LinkedIn, Clara was trained using medically reviewed women’s-health content, proprietary educational resources, and contributions from multiple women’s-health organizations. The platform was launched as a free consumer resource designed to improve access to evidence-based reproductive health information.
Clara became a centerpiece of Rescripted’s product strategy, powering conversational search, personalized educational experiences, and fertility-related guidance. The company reported that the platform helped reduce reliance on external information sources by keeping users within a medically reviewed educational ecosystem.
Rescripted’s AI initiative was supported through collaboration with seven women’s-health organizations spanning fertility, menopause, nutrition, and mental health, as reported by Future Fem Health.
With an audience reaching approximately 20 million women per month, according to the company’s launch materials cited by Fitt Insider, continued investment in AI-driven education, pharmacy services, community engagement, and fertility information infrastructure positioned Rescripted as a prominent participant in the growing intersection of reproductive health, digital media, and artificial intelligence.
Univfy Inc
Univfy’s platform applies machine learning to large datasets of fertility treatment outcomes to generate individualized predictions regarding the likelihood of success across different treatment pathways, as described on the company’s technology overview.
A key component of Univfy’s strategy has been integrating predictive models into fertility clinic workflows and patient counseling processes. Through collaborations with fertility centers and healthcare organizations, the company has sought to improve transparency around treatment expectations while supporting more personalized reproductive care planning through its clinic-focused predictive care platform.
Univfy’s predictive analytics platform has been used to support value-based fertility programs and financing initiatives designed to help patients better understand treatment options and associated costs, according to information provided through the company’s employer and payer solutions resources.
Univfy has published and presented research on individualized IVF success prediction and fertility treatment decision support through studies highlighted in its research library, by combining patient characteristics, treatment history, and clinical data.
Was Your Org Not Included?
Don't let your company miss out again.
Your company may have missed out on this coverage of your category before ESHRE, but Inside Reproductive Health overviews your category 4x per year.
Your competitors were covered because they are IVF Heroes Universe sponsors.
Don't miss out on the next coverage of your category--released before ASRM.
Over 60 leading fertility companies are leaders in the IVF Heroes Universe, isn't yours?
Year-long sponsorship is only $2,295 for the entire year, but get in now, before prices go up.